A Quarter of Doctors in Europe Can’t Define Biosimilars
This article is for subscribers only.
Companies that make copies of blockbuster biologic medicines have a marketing problem.
Almost a quarter of doctors in Europe can’t define or haven’t heard of biosimilars, according to a survey by the Alliance for Safe Biologic Medicines, an Arlington, Virginia-based trade and patient group. The survey, published today, was carried out among 470 physicians in France, Germany, Italy, Spain and the U.K.